US 12,365,876 B2
Genetically modified stem cells
Gerald F. Swiss, Rancho Santa Fe, CA (US); and David Kiewlich, Alameda, CA (US)
Assigned to SDF BioPharma, San Diego, CA (US)
Filed by SDF BioPharma Inc., Rancho Santa Fe, CA (US)
Filed on Jul. 25, 2023, as Appl. No. 18/358,659.
Application 18/358,659 is a continuation of application No. 17/522,538, filed on Nov. 9, 2021, granted, now 11,739,298.
Application 17/522,538 is a continuation of application No. 17/222,833, filed on Apr. 5, 2021, granted, now 11,186,827, issued on Nov. 30, 2021.
Application 17/222,833 is a continuation of application No. 16/826,104, filed on Mar. 20, 2020, granted, now 10,982,190, issued on Apr. 20, 2021.
Application 16/826,104 is a continuation of application No. 16/370,606, filed on Mar. 29, 2019, granted, now 10,696,950, issued on Jun. 30, 2020.
Application 16/370,606 is a continuation of application No. 16/146,980, filed on Sep. 28, 2018, abandoned.
Claims priority of provisional application 62/734,910, filed on Sep. 21, 2018.
Claims priority of provisional application 62/719,975, filed on Aug. 20, 2018.
Claims priority of provisional application 62/717,587, filed on Aug. 10, 2018.
Claims priority of provisional application 62/696,603, filed on Jul. 11, 2018.
Claims priority of provisional application 62/694,634, filed on Jul. 6, 2018.
Claims priority of provisional application 62/662,651, filed on Apr. 25, 2018.
Claims priority of provisional application 62/637,913, filed on Mar. 2, 2018.
Claims priority of provisional application 62/568,117, filed on Oct. 4, 2017.
Claims priority of provisional application 62/567,604, filed on Oct. 3, 2017.
Prior Publication US 2024/0150722 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/85 (2006.01); A61K 35/17 (2015.01); A61K 35/39 (2015.01); A61P 3/10 (2006.01); C07K 14/52 (2006.01); C12N 5/071 (2010.01); C12N 5/0781 (2010.01); C12N 5/0783 (2010.01)
CPC C12N 5/0676 (2013.01) [A61K 35/17 (2013.01); A61K 35/39 (2013.01); A61P 3/10 (2018.01); C07K 14/522 (2013.01); C12N 5/0635 (2013.01); C12N 5/0638 (2013.01); C12N 5/0646 (2013.01); C12N 5/0686 (2013.01); C12N 2501/998 (2013.01); C12N 2502/11 (2013.01); C12N 2502/99 (2013.01); C12N 2510/00 (2013.01)] 28 Claims
 
1. A transgenic human beta cell that expresses orIL overexpresses a human fugetactic agent in an amount sufficient to render said beta cell resistant to human immune cells, wherein said beta cell is capable of expressing insulin and further wherein said fugetactic agent is selected from the group consisting of CXCL12, CXCL13, gp120, and IL8.